Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 6Terminated 3Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Interventional × farletuzumab × Clear all
NCT00849667 2022-12-30

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Morphotek

Phase 3 Terminated
1,100 enrolled 30 charts
Gynecologic

Ovarian Neoplasms

NCT01018563 2021-12-08

An Open Label Extension Study of the Efficacy of MORAb-003

Morphotek

Phase 2 Terminated
3 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial

NCT00738699 2017-03-30

FAR-122

Morphotek

Phase 2 Terminated
415 enrolled 11 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡